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ABSTRACT  
Decitabine  (5-aza-2’-deoxycytidine,  aza-dCyd)  is  a  potent  DNA-demethylating  and
genotoxic  drug  used  clinically  for  the  treatment  of  myelodysplastic  syndromes  and
acute myeloid leukemia. On the other  hand, DCTPP1 and dUTPase are two “house
cleaning”  nucleotidohydrolases  involved  in  the  elimination  of  non-canonical
nucleotides.  Here we show that exposure of HeLa cells to aza-dCyd up-regulates the
expression  of  several  pyrimidine  metabolic  enzymes  including  DCTPP1,  dUTPase,
dCMP deaminase and thymidylate synthase thus suggesting their  contribution to the
cellular response to this  anticancer nucleoside.  We present  several  lines of evidence
supporting  that,  in  addition  to  the  formation  of  aza-dCMP,  an  alternative  cytotoxic
mechanism for decitabine involving the formation of aza-dUMP, a potential thymidylate
synthase  inhibitor.  Indeed,  dUTPase  or  DCTPP1  down-regulation  enhanced  the
cytotoxic effect of aza-dCyd producing an accumulation of nucleosides triphosphate
containing  uracil  as  well  as  uracil  misincorporation  and  double-strand  breaks  in
genomic DNA. Moreover, DCTPP1 hydrolyzes the triphosphate form of decitabine with
similar  kinetic  efficiency  than  its  natural  substrate  dCTP and  prevents  decitabine-
induced  global  DNA  demethylation.  We  propose  that  DCTPP1  and  dUTPase
nucleotidohydrolases are key factors in decitabine mode of action with potential value
as  predictive  markers  of  the  clinical  response  or  as  enzymatic  targets  to  improve
decitabine-based chemotherapy.  
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INTRODUCTION 
Nucleoside analogues are effective antimetabolites commonly used as anticancer agents.
The  cytidine  analog  decitabine  (5-aza-2’-deoxycytidine,  aza-dCyd)  is  a  DNA
demethylating agent and a potent anticancer drug  used clinically for the treatment of
myelodysplastic  syndromes  (MDS)  and  acute  myeloid  leukemia (1,2).  Aza-dCyd  is
metabolically activated  in vivo  through consecutive phosphorylations,  into aza-dCTP
that is readily incorporated into DNA and extended by the DNA polymerase (3). Once
in  DNA,  aza-dCyd  acts  as  a  suicidal  substrate  by  covalently  trapping  DNA
methyltransferase (DNMT) molecules that attempt to initiate cytosine methylation. The
resulting DNA-protein cross-links trigger the proteosomal degradation machinery and
lead to the depletion of the DNA methylation activities of the cell. Consequently, the
replacement of deoxycytidine (dCyd) by aza-dCyd results  in hypomethylation at  the
promoter DNA regions and the reactivation of epigenetically repressed genes  (4). The
transcriptional activation of tumor suppressor genes which are aberrantly silenced in
cancer cells constitutes the basic principle of the epigenetic cancer therapy.
The  extent  to  which  the  in  vivo antitumor  properties  of  decitabine  and the  clinical
response to decitabine treatment depend on epigenetic activities remains unclear. It has
not  been possible  to  establish a  definitive correlation between the inhibition of cell
proliferation  and  clinical  response  with  the  reversal  of  methylation  and  gene  re-
expression  (5).  In  fact,  it  is  generally  agreed  that  decitabine  has  dual  effects  on
neoplastic cells in a dose-dependent manner; at low doses, cells survive but reactivation
of  genes  that  control  proliferation  may lead  to  differentiation,  cell  cycle  arrest  and
increased apoptosis  (6). At high doses, decitabine induces genome-wide DNA damage
and cytotoxicity (7). Most of the DNA damage arises from the DNA-DNMT crosslinks
which  can block DNA synthesis and induce directly or indirectly DNA double-strand
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breaks,  eventually  leading  to  cell  death  (8).  Decitabine  has  also  been  reported  to
enhance mutagenesis, mainly point mutations and genome rearrangements most likely
due to protein-DNA crosslinks (9,10). The biochemical pathway that initiates repair of
DNA-DNMT adducts  has not  been yet  described in  detail,  however,  it  may involve
DNA double-strand break repair  factors  at  its  late  stages.  It  is  well  established that
decitabine treatment induces the activation of a specific DNA damage response that
includes  the  phosphorylation  of  histone  H2AX  (7). Additionally,  the  cytotoxic  and
mutagenic properties of decitabine may be partially derived from its intrinsic chemical
instability once  it  is  incorporated  into DNA  or  by the  accumulation of  DNA repair
intermediates  (3). Recently,  it  has  been  proposed  that  the  base  excision  repair
mechanism  (BER)  might  be  initiating  the  repair  of  decitabine-induced  DNA base
lesions although the precise nature of the damage or the DNA glycosylases involved
remains unknown (11).
The all-alpha NTP pyrophosphatase DCTPP1 (dCTP pyrophosphatase 1) is a recently
characterized pyrophosphohydrolase that contributes to the homeostasis of the dNTP
pool  in  human cells  by controlling  the  levels  of  dCTP,  one of  its  major  substrates.
DCTPP1 can also hydrolyze C5-modified dNTPs such as 5-halogenated, 5-methyl and
5-formyl  deoxycytidines,  and  therefore  may  have  an  additional  ‘house-cleaning’
function  (12). The enzyme deoxyuridine triphosphate nucleotidohydrolase (dUTPase)
also plays two roles, providing dUMP for de novo biosynthesis of dTTP and sanitizing
the deoxynucleotide pool by the specific removal of dUTP (13-15).
In this study, we have investigated the role of the nucleotidohydrolases DCTPP1 and
dUTPase  in  the  metabolic  response  to  decitabine.  We  found  that  DCTPP1  down-
regulation increased  aza-dCyd-induced  toxicity in HeLa and MRC-5 cells  at  a wide
range  of  doses.  DCTPP1 can  hydrolyze  the  activated  form of  decitabine,  5-aza-2´-
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deoxycytidine-5´-triphoshate and might constitute a novel route in the detoxification of
this DNA methylation inhibitor. In support of this notion, the analysis of the molecular
mechanism behind the  growth inhibiting  effect  revealed  that  the absence of  normal
levels of DCTPP1 had an impact on global DNA demethylation levels.  On the other
hand,  dUTPase depletion also sensitized cells to aza-dCyd and promoted a significant
accumulation of dUTP in the nucleotide pool and uracil and double-strand breaks in the
genomic DNA as a consequence of the treatment. A similar DNA damage signature was
found  in  DCTPP1-deficient  cells  exposed  to  decitabine  suggesting  the  additional
implication of this enzyme in an alternate mode of action for decitabine in which the
metabolism of aza-dCyd may ultimately lead to the genotoxic accumulation of dUTP in
the cellular pool. 
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MATERIAL AND METHODS 
Nucleotides, nucleosides and antibodies. 
Decitabine  (aza-dCyd),  cytarabine  (ara-Cyd)  and  2´-deoxycytidine  (dCyd) were
purchased from Sigma; 5-aza-2´-deoxycytidine-5´-triphosphate (aza-dCTP), ara-CTP, 2
´-difluorocytidine-5´-triphosphate  (dF-CTP)  and 2´,3´-dideoxycytidine-5´-triphosphate
(ddCTP) were obtained from Jena Bioscience. Anti-DCTPP1  (12) and anti-DUT (this
work)  are  anti-rabbit  polyclonal  antibodies  generated  in  our  laboratory.  dCMP
deaminase  (DCTD),  thymidylate  kinase  (TMPK),  thymidylate  synthase  (TS)  and
thymidine kinase (TK) detection was carried out with anti-rabbit polyclonal antibodies
from Santa Cruz Biotechnologies Inc. Cytidine deaminase (CDA) and deoxycytidine
kinase  (dCK)  were  detected  with  anti-rabbit  anti-CDA  and  anti-mouse  anti-dCK
antibodies respectively (Abcam). Anti--tubulin was purchased from Ab Frontier.
Cell cultures and transfections
Two wild-type p53-expressing cell lines were used, the normal human fibroblast line
MRC-5 (ATCC, CCL 171) and the tumor epithelial line HeLa (ATCC, CCL-2). The cell
lines  were  not  passaged  for  more  than  6  months  following  purchase.  MRC-5  was
cultured in Eagle’s Minimum Essential Medium (Gibco, Life Technologies) with 2 mM
L-glutamine (GlutaMAXTM, Gibco, Life technologies) and HeLa cell line was cultured
in Dulbecco’s Modified Eagle´s Medium (PAA, GE Healthcare) supplemented with 1X
MEM Non-essential Amino Acids Solution (Gibco, Life technologies) and 2 mM L-
glutamine. Media were supplemented with 10% fetal bovine serum (FBS), 100 U ml -1
penicillin  and 100 µg ml-1 streptomycin  (Gibco,  Life  technologies).  Cell  lines  were
cultured in a humidified atmosphere of 5 % CO2 at 37 ºC.
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DCTPP1 and dUTPase silencing were carried out with small interfering RNA (siRNA)
oligonucleotide  pool  (ON-TARGETplus  smart  pool,  Dharmacon).  The  DCTPP1-
specific  siRNAs  have  been  previously  validated  (12).  For  dUTPase silencing,  the
following mRNA sequences were targeted: 5´-GCUCAUUUGCGAACGGAUU-3´, 5´-
UGUAGGAGCUGGUGUCAUA-3´,  5´-UAGAGGAAAUGUUGGUGUU-3´  and  5´-
UGCCUAUGAUUACACAAUA-3.  The  negative  control  consisted  of  four  non-
targeting siRNAs oligonucleotides (ON-TARGETplus non-targeting pool, Dharmacon).
Transient transfections were carried out according to the manufacturer’s instructions. 
Proliferation and clonogenic assays. 
103 cells were exposed to increasing doses (0-1 mM) of decitabine, deoxycytidine or
cytarabine at 37 ºC for 24 or 72 h for Hela and MRC-5 respectively. Incubation times
were decided based on differences in cell proliferation and sensitivity to decitabine. The
medium was exchanged and the drug replenished every 24 h. Viable cell number was
determined by Resazurin (Sigma) reduction. For the clonogenic assay, cells were seeded
in a 6-well plate at a density of 300 cells per well and treated with decitabine. After
completion of the treatments, fresh growth medium was added to the wells and cells
were left  to  proliferate  for  7  (Hela)  or  12 (MRC-5) additional  days.  Colonies  were
stained with a solution of 0.5% crystal violet in methanol.
Quantification  of  DNA  methylation  by  liquid  chromatography-tandem  mass
spectrometry
DNA was isolated using the Tissue & Cell GenomicPrep MiniSpin Kit (GE Healthcare),
quantified and subjected to hydrolysis with formic acid as previously described  (12).
UPLC/MS/MS analysis was carried out using a Waters XEVO TQ-S spectrometer at the
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Center of Scientific Instrumentation (University of Granada, Spain). 
Intracellular dNTP pool size determination
dNTP levels were measured using a DNA polymerase assay with minor modifications
(16-18). Extracts were incubated in 40 µL of dUTPase buffer (34 mM Tris–HCl, pH 7.8,
5 mM MgCl2) or dUTPase buffer plus 30 ng of human dUTPase (19) for 20 min at 37
◦C. To stop the reaction, samples were precipitated with methanol, centrifuged for 20
min  at  16,000  g,  dried  and  used  for  the  quantification  of  the  dNTP pool  size  as
described (12). 
 
Quantitative determination of uracil in DNA
Uracil incorporation into DNA was measured using a qPCR-based assay following the
protocol  described  by  Horváth  and  Vértessy  (2010)  with  minor  variations  (20,21).
Genomic  DNA was  extracted  using  MasterPure  DNA Purification  Kit  (Epicentre),
digested  with  SacI-HF  (NE  Biolabs)  and  3-5  kb  fragments  containing  the  target
template (GAPDH gene), isolated and purified from 1% agarose gel. Two-fold dilution
series  of  the  DNA  samples  were  amplified  with  PfuTurbo  Hotstart  (Agilent
Technologies)  or  Taq  polymerase  (Bioline)  and  primers:  5’-  CTC
CTGCCCTTTGAGTTTGATG-3’  and  5’-  CAGCAGAGAAGCAGACAGTTATG-3’.
qPCR was performed with CFX96 Real Time System C1000 Thermal Cycler (BioRad).
Cq values obtained were used to determine uracil content as described (20). All values
are referred to non-treated control siRNA-transfected cells. 
Immunofluorescence analysis of γ-H2AX foci
Cells were grown on sterile glass coverslips, fixed with 4% paraformaldehyde for 15
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min at RT, and permeabilized in PBS containing 0.1% Triton X-100 for 10 min at RT.
Cells were then incubated with 1:250 diluted monoclonal anti-H2AX antibody (clone
JBW301,  Millipore)  for  30  min  at  37  ºC and  detected  with  secondary Alexa  488–
conjugated  goat  anti-mouse  IgG  (Invitrogen,  Life  Technologies).  Coverslips  were
dehydrated in methanol and  mounted in Vectashield with DAPI (Vector Laboratories,
Inc.).  Digital  images  were  captured  using  a  LEICA TCS SP5  confocal  microscopy
system and analyzed with FIJI/Image J.
Statistics
Results  are  expressed  as  mean  ±  standard  deviation  of  at  least  three  independent
replicates. One or two-way analysis of variance (ANOVA) followed by Dunnett’s post-
hoc  test  (referred  to  control  or  non-treated  cells)  was  used  to  analyze  the  data.
Normality and homogeneity of variance assumptions were checked for each analysis.
When the variances  were  different,  Welch  test  followed by Games-Howell  post-test
were used. A Chi-square test was performed for γH2AX-positive cells analysis. Fisher
test  was  applied  when the  assumptions  did  not  fulfill.  Differences  were  considered
significant when P-value was less than 0.05.
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RESULTS
DCTPP1 and dUTPase expression is up-regulated in response to decitabine
We have previously shown that media supplementation with an excess of deoxycytidine
induces  an  increase  in  the  expression  of  DCTPP1  in  HeLa  cells  (12).  Hence,  we
expected  that  exposure  to  decitabine  might  induce  a  similar  modulation  of  enzyme
levels in response to the accumulation of aza-dCTP. As shown in Fig. 1, the amount of
DCTPP1 protein increased up to three-fold at 24 h after addition to the medium of 10
µM aza-dCyd. At the same time, CDA, DCTD, TS and dUTPase expression was also
up-regulated, suggesting the generation of metabolic intermediates and endpoints other
than those leading to the formation of  aza-dCTP.
Depletion of DCTPP1 or dUTPase sensitizes cells to aza-dCyd.
The observation that cell exposure to decitabine translates into the overexpression of
two  house-cleaning  nucleotidohydrolases  with  capacity  to  hydrolyze  non-canonical
nucleotides, led us evaluate their potential protective role against the cytotoxic action of
aza-dCyd once activated and incorporated into the nucleotide pool.  HeLa cells were
transfected  with  a  siRNA  pool  against  DCTPP1 or  DUT and  then  treated  with
increasing  concentrations  of  the  nucleoside  analog  for  24  h.  In  all  the  experiments
performed, a non-targeting siRNA pool was used as negative control. SiRNA-mediated
depletion  of  the  proteins  was  checked  by  Western  blot  (Fig.  2A).  Strong  down-
regulation  of  DCTPP1 or  DUT led  to  increased toxicity by aza-dCyd (Fig.  2B).  In
contrast, cells transfected with the non-targeting siRNA pool did not exhibit a decrease
in viability even in the presence of 1 mM aza-dCyd. Similar results were obtained in
siRNA knock-down experiments with the non-tumoral cell line MRC-5. The protective
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effect was decitabine-specific since the absence of DCTPP1 or dUTPase did not have a
significant impact on cell proliferation after exposure to deoxycytidine or cytarabine. 
DCTPP1 or dUTPase-deficient cells incubated with decitabine also displayed a reduced
colony forming capacity compared to control cells (Fig. 2C). To investigate a potential
resistance response to decitabine mediated by DCTPP1 and dUTPase, we tested whether
the overexpression of these proteins might confer additional protection to aza-dCyd by
comparing clonogenic survival of HeLa cells both parental and overproducing DCTPP1
or dUTPase after exposure to a range of decitabine doses (Fig. 3). At 1 µM of aza-dCyd,
the  proportion  of  surviving  cells  expressing  dUTPase  was  significantly  enhanced
compared to  the number of viable  colonies obtained with cells  transfected with the
empty vector. The overexpression of DCTPP1 had no impact on cell survival at any of
the  concentrations  tested,  suggesting  that  endogenous levels  of  DCTPP1 but  not  of
dUTPase are sufficient to deal with potentially cytotoxic metabolites generated from
aza-dCyd. 
DCTPP1  modulate DNA de-methylation induced by decitabine.
Since  DCTPP1 catalyzes  the  hydrolysis  of  dCTP to  dCMP and  pyrophosphate,  we
investigated  its  potential  role  in  detoxification  of  aza-dCTP  (activated  form  of
decitabine). In vitro, DCTPP1 is active on aza-dCTP (Km = 54.04  0.34 μM and kcat =
7.54  0.03 s-1) (Fig. 4A), exhibiting kinetic parameters very similar to those obtained
for  dCTP (Km =  47.63   2.66  μM and  kcat = 5.69   0.18  s−1) (12).  The  sigmoidal
character of the aza-dCTP saturation curve and the double reciprocal plot showing non-
linear kinetics indicate that substrate binding is occurring with positive cooperativity (nH
= 2.29  0.03) (Fig. 4A). No activity was detected with other nucleotide analogs tested
such  as  ara-CTP  (cytarabine  triphosphate),  dF-CTP  (gemcitabine  triphosphate)  or
ddCTP (zalcitabine triphosphate).
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The ability of DCTPP1 to act upon aza-dCTP suggests that under decitabine exposure,
this  enzyme  may  be  preventing  the  accumulation  of  azacytosine  in  DNA  and
consequently the level of DNA methylation. To address this question,  we determined
changes in global methylation by measuring the ratio of 5-methylcytosine to cytosine by
LC-MS/MS (Fig. 4B). Under our experimental conditions, we observed a significant
decrease in global genome demethylation in control cells exposed to a dose of 100 µM
of  decitabine  for  48  hours.  Depletion  of  DCTPP1  further  increased  the  DNA
demethylating activity of decitabine, which in the absence of the nucleotidohydrolase,
caused  significant  reductions  in  the  level  of  methylcytosine  at  10  and  100  µM
concentrations.  The  methylation  data  support  a  role  for  DCTPP1 in  preventing  the
incorporation of azacytosine in cell treatments with decitabine. 
Decitabine treatment alters the nucleotide pool composition 
It has been suggested that deaminated derivatives of aza-dCyd could interfere with the
pyrimidine biosynthesis pathway by inhibiting TS (22). To investigate whether exposure
to decitabine promotes the expansion of the dUTP pool in a similar way to other TS
inhibitors such as 5-fluorouracil (23), we measured perturbations in the nucleotide pool
upon treatment with aza-dCyd and the role of the nucleotidohydrolases DCTPP1 and
dUTPase in these potential perturbations (Fig. 5).
The  DNA  polymerase-based  assay  used  to  quantify  dNTPs  does  not  allow
discrimination between dCTP and aza-dCTP nor dUTP and aza-dUTP so we will refer
to  them as  (aza-)dCTP or  (aza-)dUTP.  In  control  cells,  only the  treatment  with  the
highest  dose  of  decitabine  induced  an  important  increase  in  the  concentration  of
intracellular (aza-)dCTP (from 3.9 to 4.1 and 8.2 pmol/106 cells at 10 µM or 100 µM
respectively)  probably  due  to  the  conversion  of  aza-dCyd  to  aza-dCTP  and  the
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saturation of catabolic activities. On the other hand, the depletion of DCTPP1 promoted
a substantial accumulation of aza-(dCTP) by treatment with decitabine (from 5.6 to 13.8
and 17.3 pmol/106 cells) suggesting that DCTPP1 is likely the main catabolic activity of
the activated form of decitabine. Unexpectedly, in the absence of decitabine, DCTPP1-
silenced cells  also  exhibited  a  significant  pool  of  dUTP (0.9 pmol/106 cells)  which
cannot be detected in control cells. This pool increased by two-fold after exposure to
100 µM of decitabine (1.9 pmol/106 cells).  We hypothesize that the excess of dUTP
might be generated as a result of the allosteric activation of dCMP deaminase by the
abnormally high levels of dCTP that accumulate in these cells (12) rendering an excess
of dUMP that is subsequently converted to dUTP.
In the case of cells subjected to siRNA-mediated depletion of dUTPase and exposed to
aza-dCyd, important alterations in the nucleotide pool were observed. These alterations
consisted in  a strong increase in the intracellular amount  of pyrimidine nucleotides:
(aza-)dCTP (from 4.5 to 7.3 and 9.6 pmol/106 cells), dTTP (from 8.6 to 12.1 and 11.5
pmol/106 cells) and (aza-)dUTP (from 0.4 to 1.6 and 2.2 pmol/106 cells). While it is true
that the expansion of the dCTP pool induced by decitabine can be mostly attributed to
the formation of aza-dCTP, the increase of dTTP pools might be the consequence of an
up-regulation of dNTP synthesis in response to massive DNA damage as reported for
other genotoxic agents  (24). Indeed, in DNA-damage-stressed cells,  the synthesis of
dTTP needed  for  recovery  from DNA damage  has  been  reported  to  be  essentially
mediated by TK (24). In spite of such expanded dTTP pool, decitabine exposure caused
a two-fold increase in the dUTP/[dUTP+dTTP] ratio that elevates substantially the risk
of uracil misincorporation into DNA. 
Assessment of  uracil  and DNA damage induced by aza-dCyd in DCTPP1-  and
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dUTPase-deficient backgrounds
An expected consequence of the accumulation of dUTP in the nucleotide pool as a
result  of the treatment  with decitabine would be the misincorporation of uracil  into
DNA, especially in the absence of dUTPase. To monitor changes in the uracil genome
content in the genome, we have used the real-time PCR assay described by Horvath and
Vertessy (20) which utilizes the B-type DNA polymerase of Pyrococcus furiosus (Pfu)
and the Taq DNA polymerase for amplifications. The Pfu/Taq PCR method is based on
the fact that the DNA polymerase Pfu is strongly inhibited by uracil-containing DNA,
whereas  Taq  DNA  polymerase  can  replicate  through  the  deaminated  base.  The
differences in product formation by the two enzymes provides a mean to quantify the
amount of uracil in the DNA sample (25). Genomic DNA was obtained from HeLa cells
transfected with control,  DCTPP1 or  DUT siRNAs and treated with 0, 1, 10 and 100
µM of aza-dCyd for 24 or 48 hours. Treatment of control cells with aza-dCyd for 24
hours  produced a  significant  increase  in  the  DNA uracil  content  which  was further
enhanced after exposure to the nucleoside analog for 48 hours (P<0.00001) (Fig. 6A).
We  next  analyzed  the  presence  of  uracil  in  DCTPP1-  or  dUTPase-silenced  cells.
Consistently with the existence of an endogenous dUTP pool, DCTPP1-depleted cells
also exhibit higher constitutive levels of uracil in their genomic DNA. Concurrently
with the expansion of the dUTP pool shown in Fig. 5, DCTPP1-deficient cells exposed
to aza-dCyd also accumulated higher amounts of genomic uracil than control cells. 
Similarly to DCTPP1, the lack of dUTPase provoked an increase in the basal levels of
uracil in DNA, supporting the notion that dUTP is being constantly generated by the
normal metabolism of  the cell  and removed by dUTPase  from the  nucleotide  pool,
which this way avoids its misincorporation into DNA. DUT-silenced cells were highly
susceptible to accumulate uracil upon decitabine treatment, suggesting a major role for
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this enzyme in counteracting the formation of aza-dUTP.
Former studies have reported that cell treatment with aza-dCyd leads to the formation of
DNA double-strand breaks (DSBs) in a direct or indirect manner and also promotes the
accumulation of  γH2AX foci (H2AX phosphoserine-139),  a  hallmark of the cellular
response to DSBs (7). We proceeded to monitor  γH2AX foci by immunofluorescence
microscopy  in  DCTPP1  and  dUTPase-depleted  HeLa  cells  after  incubation  with
decitabine (Fig. 6B). Control cells exposed to 10 µM of aza-dCyd exhibited 7% of the
population with γH2AX foci, while the percentage increased up to 10% and 12% in the
absence of DCTPP1 and dUTPase respectively.  Significantly, the number of  γH2AX
positive cells induced by 100 µM aza-dCyd raised from 21% in control cells to 33% and
38% in DCTPP1- and dUTPase-silenced cells respectively, observation that correlates
with the notion that DNA breaks are a consequence of the incorporation of uracil or aza-




Catabolic  activities  may  influence  metabolism  and  thereby,  the  pharmacological
efficacy of anticancer nucleoside analogs. Mammalian cells can uptake and incorporate
decitabine into the nucleotide pool and be potentially channeled to different biochemical
pathways (Fig. 7). Decitabine can be deaminated by CDA to aza-deoxyuridine, which is
poorly  phosphorylated  by  thymidine  kinase  (26) or  alternatively,  aza-dCyd  can  be
converted  into  its  active  form  via  a  phosphorylation  pathway  that  includes  dCK,
UMP/CMP kinase and NDPK. The ability of DCTPP1 to hydrolyze the activated form
of  decitabine  and  the  hypersensitivity  of  DCTPP1-deficient  cells  exposed  to  this
nucleoside  analog  suggest  that  this  enzyme  may be  involved  in  a  novel  resistance
pathway. Indeed, our data showing an increase in cytosine demethylation in DCTPP1-
silenced cells support the notion that this nucleotidohydrolase is interfering with the
primary mode of action of decitabine and prevents the incorporation of aza-dCTP into
DNA. Since the action of DCTPP1 entails the reversion of the phosphorylation steps
involved in aza-dCyd activation,  it  is  plausible that  the relative activity ratio  of the
kinases  UMP/CMP kinase and NDPK with regard to  DCTPP1 may have predictive
clinical value in treatments with this nucleoside analog. 
Importantly, a number of evidences presented in this work suggest that aza-dCMP can
also  be  deaminated  by  dCMP deaminase  to  produce  aza-dUMP.  Early reports  have
indeed demonstrated the formation of aza-dUMP in vivo after exposure to [3H]aza-dCyd
(27).  The presence of elevated levels of aza-dCTP generated as a result of decitabine
metabolic activation would further favor deamination due to the allosteric activation of
dCMP deaminase  (28).  In addition to the potential formation of aza-dUTP, it is likely
that aza-dUMP itself acts as a competitive TS inhibitor and contributes this way to the
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accumulation of genotoxic dUTP in the nucleotide pool and the  misincorporation of
uracil in DNA. Numerous studies have established that the DNA damage associated to
uracil-DNA  is  a  significant  mechanism  of  cytotoxicity  induced  by  TS-inhibiting
chemotherapeutic agents (23). 
In agreement with this alternate genotoxic mechanism for decitabine, we have detected
a  significant  amount  of  intracellular  (aza-)dUTP after  exposure  to  aza-dCyd,  which
correlated  with  an  increased  level  of  genomic  uracil,  especially  in  the  absence  of
dUTPase  or  DCTPP1.  While  the  dUTPase  activity  removes  (aza-)dUTP from  the
nucleotide pool thus preserving genomic integrity, the absence of DCTPP1 might be
promoting decitabine cytotoxicity by two different mechanisms: it removes aza-dCTP
from the  cellular  pool  and  stimulates  the  synthesis  of  toxic  aza-dUMP derivatives
through  the  expansion  of  the  intracellular  concentration  of  (aza-)dCTP  (12) and
subsequent allosteric activation of dCMP deaminase (Fig. 7). 
We postulate that decitabine enhances uracil misincorporation into DNA and activates
base excision repair mechanisms. Indeed, a recent study has demonstrated that XRCC1
mutant cells, defective in BER, are hypersensitive to aza-dCyd and this phenotype is
associated with an accumulation of abasic sites and DNA strand breaks in genomic
DNA (11). It is therefore possible that  some of these breaks are an indication of the
formation of DNA repair intermediates induced by the presence of uracil and aza-uracil.
In summary, the data from this work suggest a novel mode of action for decitabine in
which aza-dCyd may ultimately lead to the toxic accumulation of (aza-)dUTP in the
nucleotide pool and its incorporation into the genome. DCTPP1 and dUTPase would
play an important role in this metabolic pathway and as potential factors affecting the
clinical  response  to  this  demethylating  agent,  their  expression  levels  may  have
predictive  clinical  value.  Moreover,  inhibition  of  these  nucleotidohydrolases  may
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constitute a novel approach to improve the efficacy of antitumor therapy with decitabine
and  circumvent  potential  drug  resistance  phenotypes.  Indeed,  novel  molecules  have
been recently identified with capacity to specifically inhibit the activity of dUTPase and
DCTPP1 that enhance the cytotoxic effect of pyrimidine anticancer agents (29,30) thus
highlighting  the  relevance  of  these  nucleotidohydrolases  in  the  mode  of  action  of
pyrimidine derivatives currently used in antitumour therapy. 
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Fig. 1. Modulation of enzyme expression by aza-dCyd. HeLa cells were exposed to
10 µM aza-dCyd and enzyme levels in 10 µg of protein cell extract were determined by
Western blot. Protein levels were quantified with ImageQuant image analysis software
(GE  Healthcare)  and  normalized  to  -tubulin.  DCTPP1,  dCTP pyrophosphatase  1;
CDA,  cytidine  deaminase;  DCK,  deoxycytidine  kinase;  DCTD,  dCMP deaminase;
dUTPase,  deoxyuridine  triphosphate  nucleotidohydrolase;  TS,  thymidylate  synthase;
TK,  thymidine  kinase;  TMPK,  thymidylate  kinase.  Expression  at  24  hours  was
quantified and normalized to -tubulin before representation as a diagram bar.
Fig. 2. Down-regulation of DCTPP1 and dUTPase sensitizes cells to decitabine. A,
Western  blot  analysis  of  HeLa  and  MRC-5  cells  transfected  with  DCTPP1-specific
siRNAs, DUT-specific siRNAs or a non-targeting (Control) siRNAs. Cell extracts were
prepared at the fourth day post-transfection. Protein loading was normalized with anti-
-tubulin.  B,  HeLa  and  MRC-5  cells  were  exposed  to  the  following  nucleosides:
decitabine (aza-dCyd); 2´-deoxycytidine (dCyd), and cytarabine (ara-Cyd). Percentage
of  viability was calculated  relative  to  the  number  of  viable  cells  in  the  absence  of
exogenous  nucleosides.  All  values  are  mean  ±  SD  (N=3).  Data  concerning  the
sensitivity of DCTPP1 siRNA-transfected cells to dCyd have been published elsewhere
(12) and are included for comparison purposes. C, Clonogenic capacity of  HeLa and
MRC-5 cells transfected with DCTPP1-specific siRNA, DUT-specific siRNA or a non-
targeting siRNA and treated with increasing doses of decitabine for 24 h. All values are
mean ± SD (N=4).
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Fig. 3. Effect of DCTPP1 and dUTPase overexpression on the clonogenic capacity
of cells exposed to decitabine. Left panel, Western blot showing the levels of dUTPase
and DCTPP1 proteins in HeLa cells transfected with pcDNA3-DCTPP1 (DCTPP1 OE),
pcDNA3-DUT  (DUT  OE)  or  the  empty  pcDNA3  vector  (Control).  Right  panel,
Clonogenic survival of HeLa cells expressing normal (Control) or increased levels of
DCTPP1 (DCTPP1 OE) or dUTPase (DUT OE) and treated with increasing doses of
decitabine for 24 h. All values are mean ± SD (N=3). 
Fig.  4.  DCTPP1  catalyzes  the  hydrolysis  of  aza-dCTP  and  prevents  DNA
demethylation in human cells. A, Left panel, The enzymatic assay was performed by
incubating 0.5 µM of DCTPP1 with increasing concentrations of aza-dCTP (20-250
µM)  under  optimized  reaction  conditions  as  previously  described  (12).  Kinetic
parameters and the Hill’s coefficient (nH) resulted from adjusting the data to the Hill´s
equation. All values are mean ± SD (N=3). Right panel, Double reciprocal plot showing
non-linear kinetics for aza-dCTP. B, Global DNA methylation after supplementation of
HeLa cells with 0-100 µM of aza-dCyd for 24 or 48 h. All values are mean ± SD (N=3).
Fig. 5. Effect of decitabine on the intracellular dNTP pool. Nucleotide concentration
was measured in HeLa cells transfected with non-targeting,  DCTPP1 or  DUT-specific
siRNA pools. Treatments were carried out with 0-100 µM of decitabine for 24 h. All
values are mean ± SD (N=4).
Fig. 6. Decitabine induces uracil accumulation and DNA strand breaks specially in
the absence of DCTPP1 or dUTPase. A, Uracil content in genomic DNA from HeLa
cells transfected with Control,  DCTPP1 or  DUT siRNAs and treated with 0-100 µM
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aza-dCyd for 24 or 48 h. Values resulting from genomic DNA isolated from non-treated
Control  siRNA-transfected cells  were used  as  reference.  All  values  are  mean ± SD
(N=3). P-values underlined with dotted line are referred to treated Control siRNA cells.
B,  Left  panel, Representative  microscopy images  showing  γH2AX staining  in  non-
treated or 10µM and 100 µM aza-dCyd-treated HeLa cells. All chosen fields contain a
similar  number  of  cells  as  determined by DAPI  staining  (not  shown).  Right  panel,
Percentage plots of γH2AX-positive cells in Control, DCTPP1, and DUT siRNA cells
treated with aza-dCyd. γH2AX-positive cells (> 5 foci) were scored from a total of two
hundred cells per cell line and dose. 
Fig. 7. Role of DCTPP1 and dUTPase in the response to decitabine.  Aza-dCyd is
converted into its active form via a phosphorylation pathway initiated by deoxycytidine
kinase (dCK). DCTPP1 can hydrolyze aza-dCTP and could prevent its incorporation
into DNA and the formation of DNMT-DNA cross-links. Alternatively, aza-dCyd can be
deactivated  by  cytidine  deaminase  (CDA)  to  aza-deoxyuridine  (aza-dUrd)  which  is
poorly phosphorylated by thymidine kinase (TK). The aza-dCMP intermediate can also
be  deaminated  by  dCMP deaminase  (DCTD)  to  produce  aza-dUMP,  which  might
potentially  inhibit  thymidylate  synthase  (TS).  The  accumulation  of  genotoxic
(aza-)dUTP would promote uracil misincorporation and DNA damage. 
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